|
⚲
|
| Keyboard |
| Immuno Cancer Biotherapeutics Inc | |
|---|---|
| Firm | |
| Fund # | |
| CIK # | 0002158173 |
| Sale | 2026-10-09 (0.1 M Sold) |
| Fund | |
| Phone | 6053107663 |
| Address | 48351 277th St Canton, SD 57013-5507 |
| Source | [EDGAR] |
| Amount Raised ($k) |
|---|
| Company Details | |
|---|---|
| Director | |
| Custodian | |
| Auditor | |
| Marketer | |
| Broker | |
| Jurisdiction |
| Form D Offering | |
|---|---|
| Filed | 2026-10-15 (D) |
| Exemption | 506(b) |
| Remaining | Indefinite |
| Duration | One year or less |
| Revenue | Decline to Disclose |
| Directors | Role | 2011 - 2026 |
|---|---|---|
| Stephen Collins | Director | |
| James Robl | Executive Officer |
| Comparable Firms | State | AUM |
|---|---|---|
|
Hampshire Trust LLC
✚
|
SD | |
|
Bluestem Capital Company LLC
✚
|
SD | |
|
EIDE Bailly Advisors LLC
✚
|
SD | |
|
Wells Fargo Bank N A
✚
|
SD | |
|
Capitaline Advisors LLC
✚
|
SD | |
|
Badlands Capital Management LLC
✚
|
SD | |
|
The Funding Farm LLC
✚
|
SD | |
|
Prairiegold Venture Partners LLC
✚
|
SD | |
|
Resolve Capital Management LLC
✚
|
SD | |
|
Schwan Financial Advisors LLC
✚
|
SD |